$NBIO - "This issuance strengthens our growing IP portfolio in our brain cancer treatment using Pritumumab, a unique natural antibody that crosses the blood brain barrier," said Sean Carrick, CEO of Nascent. "As we conclude our Phase I trial, this patent enhances our milestone achievements of moving the asset forward."
https://www.marketwatch.com/press-release/fis...2022-11-30